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Reagent-dependent reactivity can be described as agglutination of 
red blood cells (RBCs) in serologic testing that is not related to the 
interaction of RBC antigens and antibodies that the test system is 
intended to detect. In other words, reagent-dependent reactivity 
results in false-positive agglutination reactions in serologic 
testing. These false-positive reactions can cause confusion in 
antigen typing and RBC antibody detection and identification 
procedures, and may result in delays in patient transfusion. It is 
imperative that reagent-dependent reactivity is recognized and 
resolved during the investigation of ABO discrepancies, positive 
RBC antibody screens and antibody identification panels, and 
crossmatch reactivity. Immunohematology 2016;32:96–99.
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Chapter 43 of the fourth edition of Applied Blood Group 
Serology1 is titled “Miscellaneous Conditions That May 
Affect Results in the Blood Transfusion Laboratory.” In the 
introduction to this chapter, authors P.D. Issitt and D.J. Anstee 
write, “For those who watch Seinfeld, this is a chapter about 
nothing.” In the same vein, this article is about nothing: 
seemingly positive serologic results that generally can be 
proven to be nothing upon further investigation.
The AABB Standards for Immunohematology Reference 
Laboratories mandate that “the laboratory shall recognize 
and have a process to investigate reagent-dependent 
reactivity.”2 The need for this standard is a result of several 
testing platforms, both manual and automated, that are 
used throughout the United States for red blood cell (RBC) 
antibody detection and identification, and for the performance 
of ABO and other antigen testing of RBCs. Commercially 
prepared antisera, RBCs, and enhancement media have all 
been implicated in cases of reagent-dependent reactivity. 
Our immunohematology reference laboratory (IRL) regularly 
reports various causes of reagent-dependent reactivity to our 
client hospital transfusion services. The purpose of this article 
is to review multiple causes of reagent-dependent reactivity 
and how to recognize and resolve them.
Dyes Used in ABO Typing Reagents
Anti-A reagents contain a blue dye (such as FD&C Blue 
No. 1 and Patent Blue), and anti-B reagents contain a yellow 
dye (such as acriflavin, FD&C Yellow No. 5, and Naphthol 
Yellow);3,4 antibodies to these dyes have been reported in the 
literature.1,5 Antibodies in the patient’s plasma can combine 
with the dye in the reagent to form antigen–antibody 
complexes; in the presence of these complexes, RBCs may 
agglutinate. Alternately, the dye may bind to the RBCs, which 
are then agglutinated by an antibody directed towards the 
dye. It has also been postulated that the dye might somehow 
modify the RBC membrane so that spontaneous agglutination 
of the RBCs occurs.1 If unexpected reactions are observed 
in the ABO front (forward) type and an antibody to a dye is 
suspected, the patient’s RBCs should be washed one to two 
times to remove all traces of plasma, and the testing should be 
repeated with the washed cells.1
Additives to ABO and Other Antisera
Most commercial antisera also contain bacteriostatic 
or other preservative agents. Patient plasma may contain 
antibodies to these agents, or immune complexes may be 
formed in the presence of these reagents.1,5,6 These agents 
include chloramphenicol, gentamicin, neomycin, vancomycin, 
paraben, thimerosal, sodium azide, tetracycline, hydro-
cortisone, and other corticosteroids.1,5–7 Reactions caused 
by these additives are an in vitro phenomenon and have no 
clinical significance in transfusion therapy, other than causing 
laboratory problems that delay transfusions.7 If unexpected 
reactions are observed with any antisera, the patient’s RBCs 
should be washed one to two times to remove all traces of 
plasma, and testing should be repeated with the washed cells.
B(A) Phenomenon
A leading manufacturer of one source of anti-A includes 
the following message in the package insert for this product: 
“Anti-A may detect previously unrecognized A antigen in a 
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small number (0.1%) of Group B people. The agglutination is 
weak, mixed field, and easily dispersed.”3 This phenomenon 
is known as B(A). The package insert states that this problem 
can be resolved by testing with polyclonal anti-A or another 
monoclonal anti-A derived from a cell line other than MH04.3
RBC Preservative Problems
The package insert from one leading manufacturer 
of screening cells used in antibody detection procedures 
contains the following warning: “Infrequently, falsely 
positive results may occur in the presence of antibodies 
directed to components of the red blood cell diluent.”8 The 
chemicals in most of these commercial RBC diluents are 
adenine, chloramphenicol, glucose, inosine, neomycin sulfate, 
sodium chloride, and sodium citrate.5 All manufacturers add 
antibiotics to their RBC suspension media to reduce or prevent 
bacterial contamination;5 antibodies to any of the antibiotics 
could be present in a patient’s plasma. Some manufacturers 
also add hydrocortisone to their RBC diluents, and numerous 
examples of IgM antibodies directed towards hydrocortisone 
have been described.5 Finally, RBC diluents contain some 
source of sugar, and antibodies to one or more sugars in the 
diluent have been reported.5
An antibody to a commercial RBC diluent should be 
suspected if a laboratory reports panreactivity with screening 
or panel RBCs, but not with donor RBCs (which would lack 
the components of the commercial RBC diluent), at the same 
phase of testing. An IRL might suspect a RBC diluent problem 
if the referring laboratory uses a different source of commercial 
RBCs, and the IRL cannot duplicate the panreactivity seen in 
testing by the referring lab. Alternatively, the IRL might see 
panreactivity with one commercial source of RBCs and no 
reactivity with another commercial source of RBCs.
RBC diluent formulas are “proprietary” and vary from one 
manufacturer to the next. If an antibody to a component of 
the commercial RBC diluent is suspected, the commercial cells 
should be washed one to two times to remove the diluents, and 
the testing should be repeated. The components of the diluent 
may be washed away easily. If washing the cells is unsuccessful 
in resolving the problem, an alternate commercial source or 
fully phenotyped donor cells should be used in testing.
Antibodies to Chemicals in Commercial Antibody 
Potentiators
Albumin is rarely used as a potentiator in RBC antibody 
screening or identification procedures, but autoagglutinins 
reacting only in the presence of bovine albumin have been 
reported. In 1969, a group of researchers showed that the 
“albumin autoagglutinin phenomenon” was caused by 
antibodies in the patient’s sera reacting with sodium caprylate, 
which was added as a stabilizer during the heating phase of the 
manufacturing of bovine albumin.5 Other researchers point 
to patients with antibodies directed to the bovine albumin or 
contaminants in the bovine albumin.5
Low-ionic-strength saline (LISS) is a common potentiator 
used in tube testing as well as in gel testing and solid-
phase RBC adherence (SPRCA) assays. LISS-dependent 
autoagglutinins are detected with some regularity in the IRL. 
A LISS panagglutinin is typically suspected when all reagent 
RBCs, including the autocontrol, react at 37°C and/or the 
antihuman globulin phase, but the direct antiglobulin test 
(DAT) is negative. Thimerosal and paraben are LISS additives 
that have been implicated in this phenomenon.1,9–13 Antibody 
identification tests and the autocontrol should be repeated 
using a different potentiator such as polyethylene glycol (PEG). 
LISS-dependent reactivity should be reported when all cells 
including the autocontrol are reactive in the presence of one 
potentiator, but are nonreactive in the presence of others. The 
recommendation to the hospital is to transfuse RBCs that are 
crossmatch-compatible using a method that does not use LISS 
or another implicated potentiator.
Solid-Phase-Only Reactivity
SPRCA assays are generally automated and are well 
suited to antibody screening and antibody identification for 
transfusion services and blood bank laboratories with a high 
volume of testing and/or limited staff. Nonetheless, a small 
percentage of false-positive reactivity has been acknowledged 
by the U.S. manufacturer of this testing platform. The package 
insert reads under Specific Performance Characteristics: “Some 
patient and donor specimens were evaluated that reacted by 
Capture-R Ready-Screen, but were nonreactive by reference 
hemagglutination techniques. Most of these specimens were 
shown to contain solid-phase-only autoantibodies.”14
Our laboratory began using a manual SPRCA assay 
(Capture-R; Immucor, Norcross, GA) as an adjunct to manual 
tube RBC antibody detection and identification methods 
approximately 10 years ago. We soon realized that the test 
seemed to be “too sensitive,” as we could not detect antibody 
activity by any other method in many donor and patient 
samples. A call was made to the manufacturer’s technical 
support department, and we were told that SPRCA assays 
can detect an antibody directed at the cryptantigens of the 
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RBC membrane; these are antigens that can be exposed when 
RBC stroma is present, but not usually seen with intact RBCs. 
Therefore, we launched a joint project with the American Red 
Cross IRL in Columbus, Ohio, to investigate this so-called 
“SPRCA-only reactivity” in normal, healthy blood donors. 
A total of 283,971 donor antibody screens were performed 
in an 8-month period, and 694 donors were identified as 
having a SPRCA-only antibody; this translated to a rate of 
0.24 percent.15 The criteria used to categorize an antibody as 
SPRCA-only included the following: panreactivity in SPRCA, 
negative antibody screen in gel, negative antibody screen in 
tube using PEG, and a negative DAT.
Our laboratory regularly receives samples referred from 
client hospitals that use automated solid-phase platforms for 
antibody screens and antibody identification. Anecdotally, it 
seems that automated platforms detect more of these so-called 
SPRCA-only antibodies than does the manual SPRCA assay 
used by our laboratory; it also leads to the speculation that 
these antibodies might also be detected more frequently in a 
patient population than in a healthy, donor population. In one 
study characterizing the performance of the 2003 walk-away 
analyzer (Galileo, Immucor), the authors cited a false-positive 
rate of 1.4 percent.16 A false positive in their study was defined 
as a positive screen with a negative panel.16
A SPRCA-only antibody should be suspected if 
panreactivity is seen in an antibody identification procedure 
using a solid-phase platform and the DAT is negative. Although 
an antibody to a high-prevalence antigen or the presence of 
multiple alloantibodies would act in the same manner, it may 
be prudent to initially repeat an antibody screen on the sample 
in question with a tube method using either LISS or PEG, 
or test in a gel platform if available. If the antibody screen is 
negative with a method other than solid-phase, it is most likely 
that the solid-phase results are false positives. Obviously, if 
the antibody screen is positive by a second test method, the 
presence of antibodies must be further explored.
Practical Applications: Why Recognizing Reagent-
Dependent Reactivity Is Important
The overview of reagent-dependent reactivity in this article 
is not meant to be all-inclusive, and the information given is 
largely based on the kinds of problems referred to our IRL. As 
such, the main reason for this article is to educate readers to 
simple solutions for the resolution of these problems.
Recognizing and subsequently resolving reagent problems 
is important because it prevents the time and expense of 
referring samples to an outside laboratory. Unfortunately, 
many transfusion services have only one way of performing a 
test or approaching a problem and are reluctant to try anything 
else, even if suggested to them. The reflex decision is to send 
the sample to an IRL, which delays patient treatment and adds 
expense.
Many transfusion services have come to rely on 
automation—and rightfully so—for high-throughput testing 
and the ability to cross-train employees. Unfortunately, the 
cost of automation often means that the transfusion service 
has limited back-up resources for problem-solving. For 
example, when a client hospital reports panreactivity in a 
sample using either gel or solid-phase technology, an IRL will 
ask (after confirming that the DAT is negative), “Did you repeat 
the testing in tube?” Common responses include, “We don’t do 
that” or “We don’t do tube testing.” When tested by tube method 
by the IRL, no atypical antibodies are detected. In contrast, 
some hospitals request that the IRL attempt to duplicate their 
results using a solid-phase method even when tube testing is 
nonreactive. These unnecessary delays in patient treatment 
and charges could be prevented if the referring transfusion 
service would simply take the time to perform a tube antibody 
screen. It is a simple, low-cost test that may solve the problem 
in less than 30 minutes—yet many transfusion services are 
unwilling or unable to do this follow-up testing.
For those readers who are blood bank educators as 
well as technical specialists, perhaps it should be your role 
to teach students and employees about reagent-dependent 
reactivity. Blood bank curricula contain lectures about 
potentiators and how they work, but may not cover LISS-
dependent autoagglutinins. The principle of SPRCA is covered 
and students learn how to operate the instrument, but the 
phenomenon of SPRCA-only antibodies may not be addressed. 
Discussion of common reagent-dependent problems and their 
resolution should perhaps be as important as discussing how 
to identify a true RBC antibody. After all, a “false positive” can 
only be called that after you prove it is actually a “Seinfeld” 
nothing.
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